L-NMMA
Trials 37 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00708357 Background | May 2005 → Dec 2009 | — | Medical University of Vienna | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03534661 Comparator | Sep 2017 → Mar 2019 | hyperlipidemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01744236 Background | Apr 2013 → Aug 2015 | type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT00914394 Comparator | Oct 2010 → Jul 2011 | — | Medical University of Vienna | Terminated | No outcome recorded |
| — | NCT00806741 Comparator | Sep 2009 → Mar 2010 | — | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00580957 Background | Aug 2008 → May 2015 | obesity disorder | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00431665 Background | Jul 1999 → Jun 2000 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 50 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-NMMA | “Then, a research medication, L-NMMA, which blocks NO in the blood vessel, will be dripped into the same artery followed by another medication nitroprusside, which gives back...” NCT00240058 ↗38“L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment.” NCT02936687 ↗ “The NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA; 0.2 mg x min(-1) x dL(-1) intra-arterially) also restored the norepinephrine sensitivity.” PMID 16864730 ↗ Jul 2006 “INTERVENTION: Tilarginine (L-N(G)-monomethylarginine [L-NMMA]), 1-mg/kg bolus and 1-mg/kg per hour 5-hour infusion, vs matching placebo.” PMID 17387132 ↗ Mar 2007 “Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure” NCT00344734 ↗ “NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology.” NCT02936687 ↗ “We plan to study this with two drugs -trimethaphan and L-NMMA.” NCT00580957 ↗ “L-N^G monomethyl arginine (L-NMMA)” NCT00759707 ↗ “NG-monomethyl-L-arginine (L-NMMA)” NCT00806741 ↗ “L-Ng-monomethyl Arginine (L-NMMA)” NCT01791816 ↗ “NG-monomethyl-L-arginine (L-NMMA)” NCT00406731 ↗ “NG-monomethyl-L-arginine (L-NMMA)” NCT00914394 ↗ “NG-monomethyl-L-Arginine (L-NMMA)” NCT00431665 ↗ “NG-monomethyl-L-arginine (L-NMMA)” NCT01617551 ↗ |
| Known as | L-NG-monomethyl arginine | “INTERVENTION: Tilarginine (L-N(G)-monomethylarginine [L-NMMA]), 1-mg/kg bolus and 1-mg/kg per hour 5-hour infusion, vs matching placebo.” PMID 17387132 ↗ Mar 20074“Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min.” NCT01060930 ↗ |
| Known as | N-monomethyl-L-arginine | “Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min)” NCT02966665 ↗1“L-NMMA (N-mono.methyl-L-arginine)” NCT00410085 ↗ |
| Known as | NG-monomethyl-L-arginine | “Measurements were repeated after intra-arterial infusion of tetraethylammonium chloride (TEA; 1 µmol/min), fluconazole (0.4 µmol·min(-1)·l(-1)), and N(G)-monomethyl-L-arginine...” PMID 24925526 ↗ Jun 201416“However, we found that AF patients (n=14) were more sensitive to the pressor effects of the NO synthase inhibitor N(G)-monomethyl-l-arginine, suggesting increased NO function...” PMID 18426998 ↗ Apr 2008 “Previous studies using an NO synthase inhibitor, NG-monomethyl-L-arginine (L-NMMA) did not fully determine the NO contribution to blood pressure because of baroreflex buffering.” PMID 39090323 ↗ Aug 2024 “The NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA; 0.2 mg x min(-1) x dL(-1) intra-arterially) also restored the norepinephrine sensitivity.” PMID 16864730 ↗ Jul 2006 “Infusion of NG-monomethyl-L-arginine (L-NMMA; 6.4 µmol/min) into hand veins can cause a 20% increase in vein size in specific subjects.” PMID 21566204 ↗ May 2011 “the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, n=7)” PMID 20484484 ↗ May 2010 |
| Known as | Tilarginine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00112281 ↗ |
| Action | Inhibit | “LNMMA inhibits production of nitric oxide” NCT00004575 ↗ |
| Route | Other | “Small doses of four drugs-bradykinin, sodium nitroprusside, miconazole, and LNMMA-will be given through the arterial catheter” NCT00004575 ↗ |